Full Citation
Title: Abstract 6374: Socio-demographic predictors of recruitment in neuroblastoma therapeutic clinical trials
Citation Type: Journal Article
Publication Year: 2024
ISBN:
ISSN: 0008-5472
DOI: 10.1158/1538-7445.AM2024-6374
NSFID:
PMCID:
PMID:
Abstract: <p>The generalizability of clinical trial outcomes hinges upon the equitable access and enrollment of diverse patient populations. Yet, disparities persist that may influence enrollment patterns. In neuroblastoma, the impact of ethnicity, socioeconomic status (SES), distance to care, and age at diagnosis on enrollment in therapeutic trials remains underexplored. We aimed to investigate these factors in neuroblastoma patients to identify potential disparities in clinical trial participation. We utilized the Childhood Cancer Research Network data, selecting neuroblastoma cases from 2008-2015, excluding those &gt;21 years old or with incomplete data. We focused on factors influencing enrollment in therapeutic trials (ANBL0032, ANBL0421, ANBL0531, ANBL0532, ANBL0621, ANBL0931, ANBL1021, ANBL1221, ANBL1232). Key predictors examined were ethnicity, age at diagnosis, SES (via Yost Index), and distance to care from home to treatment hospital. We employed Poisson regression to calculate adjusted risk ratios (aRR) and 95% confidence intervals for trial participation. Analyzing 3,148 neuroblastoma cases from the CCRN registry, the ethnic composition was as follows: 68% were non-Hispanic White, 14% Hispanic, and 10% NH Black and SES distribution was even across quintiles. Age at diagnosis was a significant factor in trial enrollment: children &gt;2 years were 94% more likely to enroll than those under 2 years (p &lt; 0.001). Race, ethnicity, SES, and distance to care showed no significant effect on enrollment, all with non-significant p-values. In CCRN, neuroblastoma patient's age at diagnosis was a determinant in therapeutic trial enrollment, providing insight into design strategies to encourage trial participation. While common barriers like race, ethnicity, SES, and distance to care did not impact enrollment in our cohort, the significant role of age highlights an area where focused efforts can ensure that all age groups have equitable access to the potential benefits of therapeutic trials.</p>
Url: /cancerres/article/84/6_Supplement/6374/741717/Abstract-6374-Socio-demographic-predictors-of
Url: https://dx.doi.org/10.1158/1538-7445.AM2024-6374
User Submitted?: No
Authors: Hunter-Schlichting, DeVon; Sample, Jeannette; Knowles, Kate; Van Riper, David; Spector, Logan; Marcotte, Erin
Periodical (Full): Cancer Research
Issue: 6_Supplement
Volume: 84
Pages: 6374-6374
Countries: